Sales Performance - Sales for the quarter were $39,031,000, relatively flat from $39,000,000 in the comparable period of the prior year[57] - Domestic sales for the quarter were $29,934,000, up 4.0% from $28,772,000 in the comparable period of the prior year[57] - International sales for the quarter were $9,097,000, down 11.1% from $10,228,000 in the comparable period of the prior year[57] Financial Position - The Company's order backlog was $139.7 million at October 31, 2021, the highest in its history, compared to $96.0 million at October 31, 2020[59] - The Company had working capital of $23,049,000 at October 31, 2021, down from $26,276,000 at April 30, 2021[67] Profitability - The gross profit margin for the three months ended October 31, 2021 was 9.2%, down from 16.4% in the comparable quarter of the prior year[60] - Net loss was $3,100,000, or $(1.11) per diluted share, for the three months ended October 31, 2021, compared to a net loss of $180,000, or $(0.07) per diluted share, in the prior year period[65] Future Outlook - The Company expects improved financial performance in the second half of the fiscal year and into fiscal year 2023[73] Tax Information - The effective income tax rates for the three and six months ended October 31, 2021 were (6.8)% and (11.3)%, compared to 54.4% and 18.5% for the comparable periods of the prior year[63] Cash Flow - The Company used cash of $6,071,000 during the six months ended October 31, 2021 primarily for operations and increases in receivables[69]
Kewaunee Scientific (KEQU) - 2022 Q2 - Quarterly Report